Get the Stockscreener App
1.885
2.09%
-0.025
Aytu Biopharma Inc stock is traded at $1.885, with a volume of 48,440.
It is down -2.09% in the last 24 hours and down -20.43% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
See More
Previous Close:
$1.91
Open:
$1.97
24h Volume:
48,440
Relative Volume:
2.20
Market Cap:
$11.74M
Revenue:
$93.76M
Net Income/Loss:
$-13.68M
P/E Ratio:
-0.1835
EPS:
-10.27
Net Cash Flow:
$8.77M
1W Performance:
-6.27%
1M Performance:
-20.43%
6M Performance:
-37.87%
1Y Performance:
-35.52%
1-Day Range:
$1.87
$2.23
1-Week Range:
$1.87
$2.23
52-Week Range:
$1.87
$3.45
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St
AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com
AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle
Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada - Investing.com Canada
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada By Investing.com - Investing.com South Africa
AYTUAYTU BioPharma, Inc. Latest Stock News & Market Updates - StockTitan
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - StockTitan
Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Earnings call: Aytu BioPharma reports turnaround with focus on ADHD By Investing.com - Investing.com South Africa
Earnings call: Aytu BioPharma reports turnaround with focus on ADHD - Investing.com
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - Simply Wall St
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results - AccessWire
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 - AccessWire
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Anterix (NASDAQ:ATEX) Sees Unusually-High Trading Volume - Defense World
Atlantica Sustainable Infrastructure (NASDAQ:AY) Now Covered by StockNews.com - Defense World
Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug - Benzinga
Altamira Therapeutics announces pricing of $12M offering - TipRanks
Jupiter Asset Management Ltd. Makes New Investment in Anterix Inc. (NASDAQ:ATEX) - Defense World
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Yahoo Finance
Comparing Sanofi (NASDAQ:SNY) & Aytu BioPharma (NASDAQ:AYTU) - Defense World
Alaska Air clears hurdle in proposed merger with Hawaiian Airlines - Head Topics
Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.77 - Defense World
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 - AccessWire
Aytu BioPharma sells consumer health unit to focus on Rx products - Investing.com India
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - AccessWire
Aytu BioPharma (NASDAQ:AYTU) & SIGA Technologies (NASDAQ:SIGA) Critical Analysis - American Banking and Market News
An unknown company affiliated with Jonathan Hughes completed the acquisition of Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com
Aytu BioPharma (NASDAQ:AYTU) vs. SIGA Technologies (NASDAQ:SIGA) Financial Survey - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.89 - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Passes Below 50 Day Moving Average of $2.95 - Defense World
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Aytu BioPharma Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo News Australia
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting - Investing.com India
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Evofem Biosciences revises preferred stock terms By Investing.com - Investing.com
Analyst boosts PB Fintech stock target on strong 1Q operational trends By Investing.com - Investing.com UK
US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest Results - Yahoo New Zealand News
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):